Jupiter Neurosciences Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in JUNS.
▼ -99.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $76.50 | $802.50 | |
| P/S | — | 1612.0x | — |
| P/B | — | — | 84.9x |
| EPS | -$18.75 | -$6.00 | |
| Profit margin | — | -39662.77% | — |
| ROE | — | — | -58.48% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PULMPulmatrix, Inc. | $1.51 | — | 3.5x | — | -98.35% | $5.51M |
| CVKDCadrenal Therapeutics, Inc. | $1.54 | — | 1.2x | — | -275.16% | $5.49M |
| PMCBPharmaCyte Biotech, Inc. | $0.52 | — | 0.2x | — | -44.72% | $5.53M |
| NCNANuCana plc | $1.33 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Company description provided by Yahoo Finance.
| 0.0x |
| 0.2x |
| — |
| -70.26% |
| $5.54M |
| CDIOCardio Diagnostics Holdings, Inc. | $1.85 | — | 0.7x | — | -75.44% | $5.48M |
| LABTLakewood-Amedex Biotherapeutics Inc. | $2.30 | — | 1.2x | — | -402.83% | $5.45M |